Hims & Hers vs MEDVi: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
MEDVi beats Hims & Hers overall, scoring 8.3/10 vs 7.8/10. MEDVi is more affordable at $179/mo vs $199/mo. Choose Hims & Hers for users who want glp-1 access from a well-known, publicly trad. Choose MEDVi for users who want a low entry price with oral and injectable co.
A side-by-side comparison of Hims & Hers and MEDVi covering pricing, scores, medication types, insurance, and more to help you decide.
Hims & Hers
#25 of 39One of the largest and most recognized telehealth platforms in the US, offering compounded GLP-1 medications with a polished user experience and strong brand trust.
Visit Hims & HersMEDVi
#9 of 39Compounded GLP-1 platform offering both oral and injectable options with flexible dosing and affordable pricing.
Visit MEDVi| Feature | Hims & Hers | MEDVi |
|---|---|---|
| Our Score | 7.8/10 | 8.3/10 |
| Starting Price | $199/mo | $179/mo |
| Medication Type | Compounded | Compounded |
| Insurance Accepted | No | No |
| Best For | Users who want GLP-1 access from a well-known, publicly traded telehealth brand | Users who want a low entry price with oral and injectable compounded options |
| Ranking | #25 | #9 |
Pros & Cons Compared
Hims & Hers
Pros
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +Polished app and web experience — one of the best user interfaces in telehealth
- +$199/mo all-inclusive for compounded semaglutide with consultations and free shipping
- +Massive brand recognition means extensive customer support infrastructure and resources
Cons
- −Pivoted away from some compounded formulations after FDA crackdown — medication availability can shift
- −Compounded only — no brand-name Wegovy or Zepbound through their platform
- −Generic support experience — large patient volume means you're less likely to get personalized attention
- −Higher price than competitors like TrimRx ($179) or Enhance MD ($115) for a similar compounded product
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179/mo is competitive for a platform with both oral and injectable compounded formulations
Cons
- −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Our Verdict
MEDVi edges out Hims & Hers with a score of 8.3/10 vs 7.8/10. If budget is your priority, MEDVi starts at $179/mo compared to Hims & Hers's $199/mo. Choose Hims & Hers if you want: users who want glp-1 access from a well-known, publicly traded telehealth brand. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.